Bortezomib — CPB 0675 | AETNA Coverage Update

Aetna modified CPB 0675 for bortezomib (Velcade, Boruzu, and generics), effective February 19, 2026. Here's what billing teams need to know.

Aetna, a CVS Health company, updated its bortezomib coverage policy under CPB 0675 Aetna system. This policy governs precertification requirements and medical necessity criteria for bortezomib products billed under HCPCS codes J9041, J9046, J9048, J9049, J9051, and J9054, alongside administration codes including CPT 96401, 96409, and 96413. The policy covers 12 approved indications — ranging from multiple myeloma to systemic light chain amyloidosis — and draws a hard line on everything else.

Quick-Reference Table

Aetna Bortezomib Coverage Criteria and Medical Necessity Requirements 2026

The Aetna bortezomib coverage policy under CPB 0675 requires precertification for multiple myeloma only. All other approved indications do not list a precertification trigger in this bulletin, but that does not mean they're automatically clean claims — Aetna's plan-level design controls still apply.

For multiple myeloma cases, call Aetna precertification at (866) 752-7021 or fax (888) 267-3277 before administering. You can also submit a Statement of Medical Necessity form through Aetna's Specialty Pharmacy Precertification portal. Skipping this step on multiple myeloma is the fastest path to a claim denial.

Medical necessity for bortezomib — whether administered intravenously or subcutaneously — is satisfied when the patient's diagnosis matches one of 12 covered indications. The drug must be the Velcade brand, Boruzu brand, or a generic bortezomib product. HCPCS billing under J9041 (Velcade, 0.1 mg) is therapeutically equivalent. J9046 (Dr. Reddy's), J9048 (Fresenius Kabi), J9049 (Hospira), J9051 (Maia), and J9054 (Boruzu) are explicitly noted as not therapeutically equivalent to J9041 — this distinction matters for formulary substitution and claim-level edits at some payers.

For reauthorization, the continuation of therapy standard is straightforward: no unacceptable toxicity and no disease progression on the current regimen. Document both clearly in the clinical record before submitting.

If your patients are on Medicare, this commercial policy does not apply. Aetna routes Medicare bortezomib criteria to its separate Medicare Part B Step Therapy policy. Don't conflate the two. If you bill both commercial Aetna and Medicare Advantage Aetna plans, make sure your team knows which criteria set governs each claim.

Aetna Bortezomib Exclusions and Non-Covered Indications

This is where the policy draws a clear line. Aetna considers all indications not listed in the approved 12 to be experimental, investigational, or unproven.

There is no gray zone here. If a provider prescribes bortezomib for an off-label use not on the approved list, Aetna will deny the claim on medical necessity grounds. The policy language is unambiguous on this point.

The real exposure for billing teams is rare or emerging indications — conditions where oncologists may have clinical rationale and published case series, but where Aetna hasn't yet added the indication to CPB 0675. If you're seeing bortezomib ordered for something that doesn't appear in the 12 covered indications, flag it before you bill. Don't assume a clean claim. Talk to your compliance officer about whether a peer-to-peer or medical exception process makes sense for those cases.

Coverage Indications at a Glance

Three indications carry line-of-therapy restrictions: adult T-cell leukemia/lymphoma (single agent, subsequent therapy), Kaposi sarcoma (subsequent therapy), and Multicentric Castleman disease (subsequent therapy). For those three, document prior treatment clearly. Aetna will look for it if the claim goes to review.

Aetna Bortezomib Billing Guidelines and Action Items 2026

The effective date of February 19, 2026 is already live. If your team hasn't reviewed bortezomib billing workflows against this updated policy, do it now.

CPT, HCPCS, and ICD-10 Codes for Bortezomib Under CPB 0675

Covered HCPCS Drug Codes (When Selection Criteria Are Met)

CPT Administration Codes Related to Bortezomib Billing

Key ICD-10-CM Diagnosis Codes

The full list in CPB 0675 runs to 630 ICD-10-CM codes. Below are the primary diagnosis anchors for each covered indication. Map your patient's specific ICD-10 code against the full policy list before billing.

The ICD-10 code list in this policy is extensive. Aetna maps specific code ranges to specific indications. Run your diagnosis code through the full CPB 0675 list — don't rely on broad range assumptions.